Session Details

The text of the abstracts will be posted on Monday, November 24.

Moderator

Lindsay Peterson, Washington University in St. Louis, St. Louis, MO

Presentation numberPD8-01

Weight Trajectories in the Breast Cancer Weight Loss (BWEL) Trial (Alliance)

Chao Cao, Dana-Farber Cancer Institute, Boston, MA

Presentation numberPD8-02

Evaluating weight loss outcomes in patients with hormone receptor-positive breast cancer on endocrine therapy receiving concurrent weight loss medications

Travis Adamson, Valley Health System, Paramus, NJ

Presentation numberPD8-03

Impact of Obesity in Premenopausal Women with Early-Stage HR+/HER2- Breast Cancer Treated With Adjuvant Endocrine Therapy

Poornima Saha, Endeavor Health, Chicago, IL

Presentation numberPD8-04

Discussant: Obesity

Saba Shaikh, UT Health San Antonio, San Antonio, TX

Presentation numberPD8-05

A Retrospective Cohort Study on Mitigating Chemotherapy Side Effects in Breast Cancer Patients: The Role of GLP-1 Agonists

Elvis Obomanu, Jefferson-Eintein Hospital, Philadelphia, PA

Presentation numberPD8-06

Real-world analysis on the impact of glucagon-like peptide-1 receptor agonists on all-cause mortality and endocrine therapy-tolerability in obese breast cancer patients

Colton Jones, University of Texas Health Science Center San Antonio, San Antonio, TX

Presentation numberPD8-07

Real-world glucagon-like peptide-1 use and association with clinical characteristics, social determinants, and circulating tumor DNA positivity in patients with breast cancer

Cleo A. Ryals, Flatiron Health, New York, NY

Presentation numberPD8-08

Glp-1 receptor agonists are associated with improved breast cancer outcomes in dcis patients on hormonal therapy: a real-world cohort study

Ali Y Khan, West Virginia University, Morgantown, WV

Presentation numberPD8-09

Revisiting the GLP‑1-pCR Link in TNBC: Contrasting Outcomes in a High‑BMI, Majority‑Hispanic Cohort

Daniela Urueta Portillo, UT Health Mays Cancer Center, San Antonio, TX

Presentation numberPD8-10

Glp-1 receptor agonist in combination with radiotherapy significantly delays tumor growth and improves overall survival in a murine model of triple negative breast cancer

Shiao L Stephen, Cedars-Sinai Medical Center, Los Angeles, CA

Presentation numberPD8-11

Discussant: GLP1

Jasmine Singh Sukumar, MD Anderson Cancer Center, Houston, TX